| Literature DB >> 25257667 |
Yoko Narikawa Shiono, Ying-Fang Zheng, Masahiro Kikuya1, Masaaki Kawai, Takanori Ishida, Shinichi Kuriyama, Noriaki Ohuchi.
Abstract
BACKGROUND: It is often difficult to enrol healthy volunteers into a randomized controlled trial (RCT) as there are barriers to participants' proper understanding of a trial. This study aimed to evaluate degrees of understanding of the informed consent (IC) process among healthy volunteers who participated in an RCT. Additionally, factors associated with degree of understanding were investigated.Entities:
Mesh:
Year: 2014 PMID: 25257667 PMCID: PMC4181002 DOI: 10.1186/1745-6215-15-375
Source DB: PubMed Journal: Trials ISSN: 1745-6215 Impact factor: 2.279
Characteristics of the study participants
| N | % | ||
|---|---|---|---|
| Education level | Junior high school | 3 | 0.8 |
| High school | 96 | 25.5 | |
| Junior college* | 154 | 41.0 | |
| University, graduate school | 105 | 27.9 | |
| No reply | 18 | 4.8 | |
| Marital status | Married, living with a partner | 280 | 74.5 |
| Unmarried, widow, divorced | 78 | 20.7 | |
| No reply | 18 | 4.8 | |
| Work status | Employed | 308 | 81.9 |
| Unemployed | 49 | 13.0 | |
| No reply | 19 | 5.1 | |
| Study allocation** | Intervention group | 198 | 52.7 |
| Control group | 162 | 43.1 | |
| No reply | 16 | 4.3 |
The mean age of the participants was 43.8 years (SD = 3.1). *Junior college includes vocational school and technical college. **Participants were randomly assigned to the intervention group (screening by mammography and ultrasound) or control group (screening only by mammography) in the Japan STrategic Anti-cancer Randomized controlled Trial (J-START).
Percentage of participants by QuIC Part A score: an objective understanding of J-START
| QuIC items | QuIC scores | No | ||||
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | reply | |||
| A1. | Nature of research | When I signed the consent form for J-START, I knew that I was agreeing to participate in a clinical trial | 0.3 | 5.6 | 92.6* | 1.6 |
| A2. | Purpose of research | The main goal of J-START is improving breast cancer screening for future generations | 0.0 | 2.7 | 95.7* | 1.6 |
| A3. | Duration of procedures | I have been informed about the duration of J-START | 4.8 | 30.3 | 63.3* | 1.6 |
| A4. | Experimental nature of study | All tests in J-START are standardized | 14.6* | 26.1 | 57.5 | 1.9 |
| A5. | Purpose of research | The major purpose of J-START is to assess the effectiveness of ultrasound screening for breast cancer among Japanese women aged 40–49 years | 1.1 | 10.6 | 86.7* | 1.6 |
| A6. | Purpose of research | Neither the mammography screening nor the combined use of mammography and ultrasound screening have been proven as the best screening method for Japanese women aged 40–49 years | 0.8 | 25.3 | 72.3* | 1.6 |
| A7. | Procedures to be followed | After I agreed to participate in J-START, my examination was chosen randomly between mammography screening or combined use of mammography and ultrasound screening | 1.9 | 11.4 | 85.1* | 1.6 |
| A8. | Potential risks or discomforts | Compared with standard breast cancer screening, J-START does not carry any additional risks or discomforts | 14.1* | 35.6 | 48.7 | 1.6 |
| A9. | Benefits to self | I might not receive any direct medical benefits from my participation in J-START | 25.5 | 38.3 | 34.6* | 1.6 |
| A10. | Benefits to others | By participating in J-START, I am helping the researchers gather information that might benefit future breast cancer screening procedures | 0.3 | 10.4 | 87.8* | 1.6 |
| A11. | Confidentiality | Because I am participating in a clinical trial, it is possible that the study sponsor, various government agencies, or others who are not directly involved in my care will review my medical records | 3.7 | 33.2 | 61.4* | 1.6 |
| A12. | Alternatives to participation | My doctors did not offer me any alternative breast cancer screening procedures beyond J-START. | 87.8* | 9.3 | 1.3 | 1.6 |
| A13. | Compensation | The consent form I signed indicates who will pay for treatment if I am injured or become ill as a result of participation in this clinical trial | 14.9 | 50.3 | 33.0* | 1.9 |
| A14. | Study contacts | The informed consent form listed study contact persons | 4.8 | 19.7 | 73.7* | 1.9 |
| A15. | Voluntary nature of participation | If I had not wanted to participate in this clinical trial, I could have declined to sign the consent form | 1.1 | 11.4 | 85.6* | 1.9 |
| A16. | Voluntary nature of participation | I must remain in the clinical trial, even if I decide that I would like to withdraw someday | 60.1* | 30.1 | 8.2 | 1.6 |
Quality of Informed Consent (QuIC) is a scale for assessing participants’ understanding of clinical trials. Part A assesses objective understanding and Part B assesses subjective understanding. QuIC Part A possible responses are 1 (quite disagree), 2 (unsure) and 3 (totally agree) [6]. *Correct answer. J-START, Japan STrategic Anti-cancer Randomized controlled Trial.
Percentage of participants by QuIC Part B score: a subjective understanding of J-START
| QuIC questions | QuIC scores | No | ||||||
|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | reply | |||
| B1. | Nature of research | This breast cancer screening involves a research component | 1.1 | 2.1 | 3.7 | 39.6 | 51.6 | 1.9 |
| B2. | Purpose of research | What the researchers are trying to understand in J-START | 0.3 | 1.1 | 1.6 | 36.7 | 59.0 | 1.3 |
| B3. | Duration of procedures | How long you will be in J-START | 1.9 | 7.2 | 9.0 | 33.8 | 46.8 | 1.3 |
| B4. | Procedures to be followed | The tests and procedures you will undergo | 1.1 | 0.8 | 2.7 | 30.6 | 62.2 | 2.7 |
| B5. | Experimental nature of study | Which of these tests and procedures are experimental | 1.1 | 4.3 | 7.5 | 38.6 | 39.4 | 9.3 |
| B6. | Potential risks or discomforts | The potential risks or discomforts associated with participating in J-START | 1.9 | 4.5 | 13.8 | 34.8 | 43.4 | 1.6 |
| B7. | Benefits to self | The potential benefit to you for participating in J-START | 2.1 | 1.9 | 14.4 | 42.0 | 37.8 | 1.9 |
| B8. | Benefits to others | How your participation in this clinical trial might benefit future patients | 0.3 | 0.3 | 2.4 | 31.4 | 64.1 | 1.6 |
| B9. | Alternatives to participation | The alternative to participation in the clinical trial | 0.8 | 1.3 | 6.4 | 28.5 | 61.4 | 1.6 |
| B10. | Confidentiality | The effect of clinical trial participation on the confidentiality of your medical records | 0.5 | 0.0 | 3.2 | 30.1 | 64.9 | 1.3 |
| B11. | Compensation | Who will pay for treatment if you are injured or become ill due to participation in J-START | 14.9 | 19.4 | 18.4 | 21.8 | 22.9 | 2.7 |
| B12. | Study contacts | Whom you should contact if you have questions or concerns regarding J-START | 4.5 | 6.4 | 11.7 | 31.9 | 43.9 | 1.6 |
| B13. | Voluntary nature of participation | The fact that participation in J-START is voluntary | 0.5 | 0.3 | 0.3 | 17.8 | 79.8 | 1.3 |
| B14. | Overall | Overall, how well did you understand your specified clinical trial when you signed the consent form? | 0.8 | 2.4 | 4.5 | 65.7 | 25.3 | 1.3 |
Quality of Informed Consent (QuIC) is a scale for assessing participants’ understanding of clinical trial procedures. Part A assesses objective understanding and Part B assesses subjective understanding [6]. QuIC Part B responses were as follows: 1 for “did not understand”, 2 for “almost did not understand”, 3 for “neither understood nor didn’t understand”, 4 for “generally understood”, and 5 for “understood very well”. J-START, Japan STrategic Anti-cancer Randomized controlled Trial.
Questionnaire on participants’ impression of the informed consent process
| Item | Categories | N | % |
|---|---|---|---|
|
| |||
| Did you know about “RCTs” before participating in J-START? | Yes | 108 | 28.7 |
| No | 268 | 71.3 | |
| Did you know about J-START before the informed consent procedure? | Yes | 97 | 25.8 |
| No | 279 | 74.2 | |
|
| |||
| Did the information leaflet help you understand J-START? | Helpful | 266 | 70.7 |
| Unsure | 62 | 16.5 | |
| No | 48 | 12.8 | |
| Did the educational video help you understand J-START? | Helpful | 277 | 73.7 |
| Unsure | 25 | 6.7 | |
| No | 74 | 19.7 | |
|
| |||
| Did the research staff confirm your understanding? | Yes | 346 | 92.0 |
| Unsure | 17 | 4.5 | |
| No | 9 | 2.4 | |
| Missing | 4 | 1.1 | |
| Did you need further information? | Yes | 10 | 2.7 |
| Unsure | 58 | 15.4 | |
| No | 299 | 79.5 | |
| Missing | 9 | 2.4 | |
| I had sufficient opportunity to ask questions | Yes | 338 | 89.9 |
| Unsure | 14 | 3.7 | |
| No | 20 | 5.3 | |
| Missing | 4 | 1.1 | |
| I had enough time to understand information | Yes | 259 | 68.9 |
| Unsure | 102 | 27.1 | |
| No | 12 | 3.2 | |
| Missing | 3 | 0.8 | |
| Did you find it easy to refuse participation? | Yes | 285 | 75.8 |
| Unsure | 60 | 16.0 | |
| No | 23 | 6.1 | |
| Missing | 8 | 2.1 | |
J-START, Japan STrategic Anti-cancer Randomized controlled Trial; RCT, randomized controlled trial.
Factors associated with low comprehension scores of QuIC Part A items
| A4. Experimental nature of study | A8.Potential risks or discomforts | A9. Benefit to self | A13. Compensation | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Quite disagree* | Unsure | Totally agree |
| Quite disagree* | Unsure | Totally agree |
| Quite disagree | Unsure | Totally agree* |
| Quite disagree | Unsure | Totally agree* |
| |
|
| ||||||||||||||||
| Site A | 3.5% | 7.1% | 12.7% | 0.54 | 3.0% | 6.5% | 13.8% | 0.009 | 5.7% | 8.7% | 8.9% | 0.927 | 0.8% | 6.5% | 16.0% | <0.0001 |
| Site B | 1.1% | 3.3% | 5.4% | 2.7% | 4.1% | 3.0% | 3.2% | 3.5% | 3.0% | 2.2% | 6.0% | 1.6% | ||||
| Site C | 6.5% | 9.2% | 22.2% | 4.3% | 14.3% | 19.2% | 9.2% | 14.6% | 14.1% | 7.6% | 21.7% | 8.7% | ||||
| Site D | 3.0% | 4.1% | 8.9% | 3.5% | 6.8% | 5.7% | 3.8% | 7.0% | 5.1% | 1.6% | 9.8% | 4.6% | ||||
| Site E | 0.8% | 3.0% | 9.2% | 0.8% | 4.6% | 7.8% | 4.1% | 5.1% | 4.1% | 3.0% | 7.3% | 2.7% | ||||
|
| ||||||||||||||||
| Yes | 6.2% | 9. 8% | 13.0% | 0.002 | 5.4% | 10.5% | 13.0% | 0.266 | 6.5% | 11.9% | 10.5% | 0.613 | 4.1% | 16.0% | 8.9% | 0.629 |
| No | 8.7% | 16.8% | 45.5% | 8.9% | 25.7% | 36.5% | 19.5% | 27.0% | 24.6% | 11.1% | 35.2% | 24.7% | ||||
|
| ||||||||||||||||
| Yes | 6.5% | 7.1% | 12.5% | 0.003 | 3.5% | 8.7% | 13.8% | 0.703 | 6.2% | 11.4% | 8.4% | 0.529 | 4.1% | 13.8% | 8.1% | 0.851 |
| No | 8.4% | 19.5% | 46.1% | 10.8% | 27.6% | 35.7% | 19.7% | 27.6% | 26.8% | 11.1% | 37.4% | 25.5% | ||||
|
| ||||||||||||||||
| Yes | 9.8% | 19.8% | 44.2% | 0.538 | 9.5% | 24.6% | 39.5% | 0.003 | 19.2% | 27.0% | 27.3% | 0.517 | 9.2% | 35.5% | 29.0% | 0.001 |
| No | 1.1% | 1.4% | 4.1% | 0.3% | 4.3% | 2.2% | 1.4% | 3.5% | 1.9% | 1.1% | 4.3% | 1.1% | ||||
| Unsure | 4.1% | 5.4% | 10.3% | 4.6% | 7.3% | 7.8% | 5.4% | 8.4% | 6.0% | 4.9% | 11.4% | 3.5% | ||||
|
| ||||||||||||||||
| Yes | 14.1% | 23.9% | 51.8% | 0.411 | 14.1% | 30.8% | 44.9% | 0.025 | 25.1% | 33.5% | 31.1% | 0.023 | 13.3% | 44.4% | 32.0% | 0.049 |
| No | 0.8% | 2.7% | 6.8% | 0.3% | 5.4% | 4.6% | 0.8% | 5.4% | 4.1% | 1.9% | 6.8% | 1.6% | ||||
|
| ||||||||||||||||
| Yes | 9.8% | 17.9% | 40.7% | 0.828 | 9.2% | 21.6% | 37.6% | 0.007 | 18.1% | 25.7% | 24.6% | 0.729 | 9.2% | 32.8% | 26.3% | 0.013 |
| No | 5.2% | 8.7% | 17.9% | 5.1% | 14.6% | 11.9% | 7.8% | 13.2% | 10.5% | 6.0% | 18.4% | 7.3% | ||||
|
| ||||||||||||||||
| Yes | 11.7% | 18.7% | 45.0% | 0.409 | 10.5% | 25.4% | 39.5% | 0.137 | 22.4% | 25.7% | 27.3% | 0.001 | 13.0% | 36.0% | 26.3% | 0.043 |
| No | 3.3% | 7.9% | 13.6% | 3.8% | 10.8% | 10.0% | 3.5% | 13.2% | 7.8% | 2.2% | 15.2% | 7.3% | ||||
*Correct answer. J-START, Japan STrategic Anti-cancer Randomized controlled Trial; RCT, randomized controlled trial.